个人简介
2018.1-至今 中国科学院广州生物医药与健康研究院，研究员
2013.1-2017.12 中国科学院广州生物医药与健康研究院，副研究员
2010.7-2012.12 中国科学院广州生物医药与健康研究院，助理研究员
2005.9-2010.6 中国科学院广州生物医药与健康研究院，生物技术与医药，博士
2001.9-2005.6 南京大学，环境科学，学士
承担科研项目情况：
1. 国家自然科学基金（面上项目，31470892），新型流感病毒载体艾滋病疫苗诱导黏膜免疫反应的作用及机制研究。
2. 国家重点研发计划（2016YFC1200900），重要新发突发病原体应急处置技术与产品研究。
3. 国家重大传染病专项（2017ZX10204401），抗H7N9病毒血浆在H7N9感染重症治疗的临床应用。
4. “珠江科技新星”专项（201506010076），多抗原联用的多价治疗性结核疫苗研究。
5. 广州市健康医疗协同创新重大专项（201400000002），呼吸道新发突发及重大传染病综合防诊治。
6. 广州市健康医疗协同创新重大专项（201508020252），病毒感染重症救治的特异性被动免疫应用研究及腺病毒单克隆抗体药物研发。
研究领域
1. 新发突发及重要传染病疫苗。
新发突发传染病给疫区人群乃至全球公共卫生带来重大威胁。疫苗是疫情防控的最有效工具，本团队致力于利用基因工程改造的腺病毒载体研制应对新发突发传染病的疫苗。
2. 新型疫苗载体。
通过分子流行病学筛找具独特感染特性的腺病毒，以基因工程改造为复制缺陷型基因载体，用于创新疫苗或免疫治疗策略的研制。
3. 过敏性哮喘的免疫治疗。
过敏性哮喘发病率逐年上升，而依赖于糖皮质激素等的治疗策略依从性较差且长期使用易发生耐药。我们拟以腺病毒载体携带结核抗原等，研制免疫治疗新策略
近期论文
查看导师新发文章
（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）
1. Ying Feng, Xikui Sun, Xianmiao Ye, Yupeng Feng, Jinlin Wang, Xuehua Zheng, Xinglong Liu, Changhua Yi, Mingli Hao, Qian Wang, Feng Li, Wei Xu, Liang Li, Chufang Li, Rong Zhou, Ling Chen* and Liqiang Feng*. Hexon and fiber of adenovirus type 14 and 55 are major targets of neutralizing antibody but only fiber-specific antibody contributes to cross-neutralizing activity. Virology. 2018, 518: 272–283.
2. Yiling Zhang, Ying Feng, Liang Li, Xianmiao Ye, Jinlin Wang, Qian Wang, Pingchao Li, Na Li, Xuehua Zheng, Xiang Gao, Chufang Li, Feng Li, Baoqing Sun, Kefang Lai, Zhong Su, Nanshan Zhong, Ling Chen*, Liqiang Feng*. Immunization with an adenovirus-vectored TB vaccine containing Ag85A-Mtb32 effectively alleviates allergic asthma. Journal of Molecular Medicine. 2018, 96(3-4):249-263.
3. Xuehua Zheng, Xia Rong, Ying Feng, Xikui Sun, Liang Li, Qian Wang, Min Wang，Wenkuan Liu, Chufang Li, Yiyu Yang, Rong Zhou, Jiahai Lu, Liqiang Feng* and Ling Chen*. Seroprevalence of neutralizing antibodies against adenovirus type 14 and 55 in healthy adults in Southern China. Emerging Microbes & Infections. 2017, 6: e43.
4. Yiling Zhang, Liqiang Feng*, Liang Li, Dimin Wang, Chufang Li, Caijun Sun, Pingchao Li, Xuehua Zheng, Yichu Liu, Wei Yang, Xuefeng Niu, Nanshan Zhong & Ling Chen. Effects of the fusion design and immunization route on the immunogenicity of Ag85A-Mtb32 in adenoviral vectored tuberculosis vaccine. Human Vaccines & Immunotherapeutics. 2015, 11(7):1803-1813.
5. Lijun Xiao, Dimin Wang, Caijun Sun, Pingchao Li, Yi Jin, Liqiang Feng*, Ling Chen*. Enhancement of SIV-specific cell mediated immune responses by co-administration of soluble PD-1 and Tim-3 as molecular adjuvants in mice. Human Vaccines & Immunotherapeutics. 2013, 10(3): 724-733.
6. Feng Li, Liqiang Feng, Weiqi Pan, Zhenyuan Dong, Chufang Li, Caijun Sun, Ling Chen*. Generation of replication-competent recombinant influenza A viruses carrying a reporter gene harbored in neuraminidase segment. Journal of Virology. 2010, 84(22):12075-12081.
7. Liqiang Feng, Feng Li, Yichu Liu, Xuehua Zheng, Biliang Zhang, Ling Chen*. A convenient plasmid-based system containing three reporter genes for real-time and quantitative analysis of messenger RNA silencing. Analytical Biochemistry. 2009, 394(2):284-286.
8. Liqiang Feng, Feng Li, Xuehua Zheng, Weiqi Pan, Kai Zhou, Yichu Liu, Hongxuan He, Ling Chen*. The mouse Pol I terminator is more efficient than the hepatitis delta virus ribozyme in generating influenza-virus-like RNAs with precise 3’ ends in a plasmid-only-based virus rescue system. Archives of Virology. 2009, 154(7):1151-1156.
京公网安备 11010802027423号